Avalon Bioventures

Avalon BioVentures, based in La Jolla, California, is a leading venture capital firm dedicated to early-stage biomedical innovation. With a $135 million fund, ABV1, Avalon BioVentures continues the legacy of Avalon Ventures by focusing exclusively on life sciences. Notable investments include Vertex Pharmaceuticals, Onyx Pharmaceuticals, Amira Pharmaceuticals, and Neurocrine Biosciences. More recent successes include Sitari Pharmaceuticals (acquired by GSK), Calporta (acquired by Merck), and Synthorx (acquired by Sanofi). Avalon BioVentures concentrates on biotechnology and life sciences, investing primarily in companies that are developing groundbreaking therapies for unmet clinical needs. Geographically, the firm focuses on the U.S., leveraging its strong presence in San Diego’s vibrant biotech hub. The firm’s strategy involves more than just capital; it includes active partnership through their integrated life science accelerator, providing essential resources, operational support, and strategic guidance from day one. Avalon BioVentures typically leads investment rounds, with average checks ranging from early seed funding to larger Series A investments. Key team members include Jay Lichter, Ph.D., an experienced biotech executive, Sanford J. Madigan, Ph.D., who has a rich background in corporate financing and business development, and Sergio G. Duron, Ph.D., known for his extensive experience in drug discovery and preclinical development. These leaders, among others, bring a combination of scientific expertise and entrepreneurial acumen, ensuring a hands-on approach to building successful biotech companies. Startups seeking investment should approach Avalon BioVentures with a clear vision for innovation in life sciences and a readiness to engage in a collaborative, entrepreneurial partnership.